Anticoagulation for venous thromboembolism
BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39161.665579.BE (Published 29 March 2007) Cite this as: BMJ 2007;334:645- John W Eikelboom, thrombosis physician (eikelbj@mcmaster.ca),
- Jeffrey S Ginsberg, thrombosis physician,
- Jack Hirsh, thrombosis physician
- Department of Medicine, McMaster University, Hamilton, ON, Canada L8N 8Z5
The optimal duration of anticoagulant therapy for the treatment of venous thromboembolism has been the subject of many randomised trials over the past 15 years.1 2 The results indicate no clear advantage for many patients of prolonging warfarin beyond three to six months, because of the risk of bleeding and the inconvenience. The annual incidence of major bleeding in patients who take warfarin for longer than three months is 2-3%, with an estimated case fatality rate of 9.1% (95% confidence interval 2.5% to 21.7%).3 Also, duration of treatment has little effect on the long term risk (after the first three months) of recurrence. Trials have shown that the frequency of recurrence at two to three years is similar in patients taking three months or 12 months of oral anticoagulation.1 2 …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.